Korsana Biosciences Emerges from Stealth with $175 Millon in Funding to Advance Potential Best-in-Class Therapeutics for Neurodegenerative Diseases
Lead program KRSA-028 is a next-generation shuttled monoclonal antibody targeting amyloid beta for the treatment of Alzheimer’s disease KRSA-028 preclinical data support potential for a best-in-class therapeutic profile enabled by THETA™, Korsana’s proprietary TfR1-based therapeutic…